In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.

JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.

Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.